228 related articles for article (PubMed ID: 19678746)
1. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer.
Kebebew E; Lindsay S; Clark OH; Woeber KA; Hawkins R; Greenspan FS
Thyroid; 2009 Sep; 19(9):953-6. PubMed ID: 19678746
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer.
Kebebew E; Peng M; Reiff E; Treseler P; Woeber KA; Clark OH; Greenspan FS; Lindsay S; Duh QY; Morita E
Surgery; 2006 Dec; 140(6):960-6; discussion 966-7. PubMed ID: 17188145
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma.
Tepmongkol S; Keelawat S; Honsawek S; Ruangvejvorachai P
Thyroid; 2008 Jul; 18(7):697-704. PubMed ID: 18630997
[TBL] [Abstract][Full Text] [Related]
4. Enhanced radioiodine uptake in a patient with poorly differentiated papillary thyroid cancer after treatment with rosiglitazone.
Elias AN; Lizotte P
Clin Nucl Med; 2006 Sep; 31(9):517-9. PubMed ID: 16921272
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study.
Simon D; Körber C; Krausch M; Segering J; Groth P; Görges R; Grünwald F; Müller-Gärtner HW; Schmutzler C; Köhrle J; Röher HD; Reiners C
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):775-82. PubMed ID: 12029551
[TBL] [Abstract][Full Text] [Related]
6. [Rosiglitazone in two patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer: preliminary results].
Martín T; Torres A; Cambil T; Castro J
Med Clin (Barc); 2008 Oct; 131(11):435. PubMed ID: 18928727
[No Abstract] [Full Text] [Related]
7. Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers.
Philips JC; Petite C; Willi JP; Buchegger F; Meier CA
Nucl Med Commun; 2004 Dec; 25(12):1183-6. PubMed ID: 15640776
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.
Nilubol N; Merkel R; Yang L; Patel D; Reynolds JC; Sadowski SM; Neychev V; Kebebew E
Clin Endocrinol (Oxf); 2017 Jan; 86(1):128-133. PubMed ID: 27392538
[TBL] [Abstract][Full Text] [Related]
9. Effects of rosiglitazone on radioiodine negative and progressive differentiated thyroid carcinoma as assessed by ¹²⁴I PET/CT imaging.
Rosenbaum-Krumme SJ; Freudenberg LS; Jentzen W; Bockisch A; Nagarajah J
Clin Nucl Med; 2012 Mar; 37(3):e47-52. PubMed ID: 22310270
[TBL] [Abstract][Full Text] [Related]
10. Comparison of thyroglobulin and radioiodine scintigraphy during follow-up of patients with differentiated thyroid carcinoma.
Johansen K; Woodhouse NJ
Eur J Med; 1992 Nov; 1(7):403-6. PubMed ID: 1341479
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin.
Hughes DT; Miller BS; Cohen MS; Doherty GM; Gauger PG
Ann Surg Oncol; 2014 May; 21(5):1647-52. PubMed ID: 24385210
[TBL] [Abstract][Full Text] [Related]
12. Unusual case of well-differentiated papillary thyroid carcinoma lacking thyroglobulin expression while still concentrating radioiodine.
Singh B; Bollmann R; Ahmadzadehfar H; Biersack HJ; Ezziddin S
Br J Radiol; 2006 Sep; 79(945):e84-7. PubMed ID: 16940367
[TBL] [Abstract][Full Text] [Related]
13. [Redifferentiation therapy with rosiglitazone in a case of differentiated thyroid cancer with pulmonary metastases and absence of radioiodine uptake].
Elola M; Yoldi A; Emparanza JI; Matteucci T; Bilbao I; Goena M
Rev Esp Med Nucl; 2011; 30(4):241-3. PubMed ID: 21334106
[TBL] [Abstract][Full Text] [Related]
14. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients.
Schlumberger M; Lacroix L; Russo D; Filetti S; Bidart JM
Nat Clin Pract Endocrinol Metab; 2007 Mar; 3(3):260-9. PubMed ID: 17315034
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer.
Lim I; Kim SK; Hwang SS; Kim SW; Chung KW; Kang HS; Lee ES
Ann Nucl Med; 2012 Dec; 26(10):777-86. PubMed ID: 22869417
[TBL] [Abstract][Full Text] [Related]
16. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
17. Management of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scans.
Clark OH; Hoelting T
Thyroid; 1994; 4(4):501-5. PubMed ID: 7711516
[TBL] [Abstract][Full Text] [Related]
18. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
20. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.
Luster M; Lassmann M; Haenscheid H; Michalowski U; Incerti C; Reiners C
J Clin Endocrinol Metab; 2000 Oct; 85(10):3640-5. PubMed ID: 11061516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
